tirzepatide surpass SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized New Dual Incretin Agonist for
Description
Tap and distilled water are not sterile
When appetite and food behaviour shift, associated habits sometimes shift with them
They're different bets on which hormonal combination produces the best outcome and right now, only one of those bets has been tested at Phase 3 scale
Also, while it is usually fine to eat dairy, it is best to monitor individual tolerance since some people may experience unique reactions to combining dairy with their medication
